Clinical trials: Biliary Cancer, open to volunteers
GI Cancer
Effect of Geriatric Intervention in Frail Patients with Gastric, Biliary, and Pancreatic Cancer Receiving Palliative Chemotherapy
Gastric, biliary and pancreatic cancer are commonly malignancies from gastro- intestinal tract in Taiwan. Because lack of specific symptoms at presentation and effective screening methodology, majority of these patients are…
- Trial name
- NCT06040801
- Testing
- Frailty intervention measures
- Where
- Taiwan
- Volunteers
- 138 people
- Sponsor
- Chang Gung Memorial Hospital
Malignancy, Digestive Cancer
Target-specific immunoPET Imaging of Digestive System Carcinoma
The aim of this study is to establish and optimize the target-specific PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging…
- Conditions
- Malignancy, Digestive Cancer, Digestive System Neoplasm, Digestive System Carcinoma
- Trial name
- NCT06715839
- Testing
- [68Ga]Ga-DOTA-H2D3, [18F]F-RESCA-RB14, [68Ga]Ga-NOTA-T4
- Where
- China
- Volunteers
- 400 people
- Sponsor
- RenJi Hospital
Liver Injury, Secondary to Immune Checkpoint Inhibitors
Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis
Background and Study Rationale Immune checkpoint inhibitors (ICI) are a breakthrough cancer treatment that boosts the immune system to fight tumors.
- Conditions
- Liver Injury, Secondary to Immune Checkpoint Inhibitors, Cancer Patients
- Trial name
- CO-CHILI (NCT06864481)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Montpellier
Biliary Tract Neoplasms Immunotherapy
Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Explore the impact of the first-line application of Pembrolizumab with or without Lenvatinib or chemotherapy, on the survival, disease progression, and drug safety of patients with advanced biliary tract cancers
- Trial name
- NCT06230471
- Testing
- Pembrolizumab,Lenvatinib and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）, Pembrolizumab and Lenvatinib, Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Advanced Solid Tumors, Ewing Sarcoma
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
- Conditions
- Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07197554
- Testing
- ST-01156
- Where
- 6 sites in United States
- Volunteers
- 171 people
- Sponsor
- SEED Therapeutics, Inc.
Biliary Tract Neoplasms Immunotherapy
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer
An investigation into the survival outcomes, progression-free survival, and safety of triple therapy with Trastuzumab Rezetecan, Adebrelimab, and Lenvatinib in patients with advanced HER2-positive/low-expressing biliary tract…
- Trial name
- NCT07704177
- Testing
- Trastuzumab Rezetecan, Adebrelimab, Lenvatinib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking Union Medical College Hospital
Pancreas Cancer, Cholangiocarcinoma
The Relationship Between Triceps Skinfold and Overall Survival of Pancreas, Bile Duct, Gallbladder Cancer
In this study, the investigators aim to demonstration of relationship between triceps skinfold thickness and overall survival of pancreatic cancer, cholangiocarcinoma and GB cancer.
- Conditions
- Pancreas Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- NCT03637569
- Testing
- Measurement of triceps skinfold thickness
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Samsung Medical Center
KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors…
- Conditions
- KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
- Trial name
- NCT07458347
- Testing
- KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab
- Where
- 9 sites in United States
- Volunteers
- 545 people
- Sponsor
- Kestrel Therapeutics, Inc.
Cholangiocarcinoma
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure…
- Trial name
- NCT05874414
- Testing
- GNS561 + Trametinib
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 98 people
- Sponsor
- Genfit
Advanced Solid Cancers
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are.
- Trial name
- NCT07186842
- Testing
- BNT329, CA19-9-targeting monoclonal antibody
- Where
- 18 sites in United States, Australia and 3 more
- Volunteers
- 245 people
- Sponsor
- BioNTech SE
Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Based on preclinical data from the Lim lab (WUSM), the investigators hypothesize that IRAK4 inhibition cripples tumor-intrinsic survival signaling and effectively overcomes the desmoplastic and immune-suppressive tumor…
- Trial name
- NCT07107750
- Testing
- Emavusertib, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma
Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
Clinical trial phase: Phase 2 Intervention model: Control group Group allocation: Randomized controlled trial Research perspective: Prospective study Participating centers: Multicenter study Definition of the intervention period…
- Conditions
- Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma, Unresectable Biliary Tract Carcinoma
- Trial name
- Dulastin (NCT06135896)
- Testing
- Tripegfilgrastim
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- National Cancer Center, Korea
Biliary Track Cancer
Histotripsy in Biliary Tract Cancer
The purpose of this pilot study is to examine the safety and feasibility of histotripsy in two cohorts of 12 patients each with Biliary Track Cancer (BTC), with a plan to expand to a larger multi-center study if both safety and…
- Trial name
- NCT07853690
- Testing
- Gemcitabine, Cisplatin, Durvalumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NYU Langone Health
Primary Sclerosing Cholangitis, PSC
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
The purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to learn more about changes that occur in the liver.
- Conditions
- Primary Sclerosing Cholangitis, PSC, Cholangiocarcinoma
- Trial name
- NCT04753996
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Gastric Cancer, Gastroesophageal Junction Cancer
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06219941
- Testing
- AZD0901, 5-Fluorouracil, Leucovorin
- Where
- 52 sites in United States, Australia and 12 more
- Volunteers
- 226 people
- Sponsor
- AstraZeneca
Selected Advanced Solid Tumors, Colorectal Cancer (CRC)
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
This Phase 1, open-label study will evaluate two investigational radiopharmaceuticals in adults with selected advanced or metastatic solid tumors.
- Conditions
- Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07812805
- Testing
- SKL35501, SKL35502
- Where
- 5 sites in United States, South Korea
- Volunteers
- 100 people
- Sponsor
- SK Life Science, Inc.
Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc)
A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening
Biliary tract carcinoma (BTC), including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma, ranks sixth in incidence among gastrointestinal malignancies and tenth in cancer-related mortality…
- Conditions
- Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma
- Trial name
- NCT07176962
- Where
- China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Yingbin Liu, MD, PhD, FACS
Pancreatic Cancer, Periampullary Cancer
Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas
This is a single-center, randomized controlled trial comparing the efficacy of pancreaticojejunostomy with modified N-butyl-2-cyanoacrylate(Glubran® 2) versus standard pancreaticojejunostomy without cyanoacrylate in preventing…
- Conditions
- Pancreatic Cancer, Periampullary Cancer, Duodenal Cancer, Cholangiocarcinoma
- Trial name
- NBCA-MS (NCT07155525)
- Testing
- Pancreaticojejunostomy with Modified N-Butyl-2-Cyanoacrylate (Glubran® 2), Standard(duct-to-mucosa) Pancreaticojejunostomy
- Where
- Egypt
- Volunteers
- 194 people
- Sponsor
- Minia University
Biliary Tract Cancer (BTC)
Daraxonrasib in Asian RAS-mutant Biliary Tract Cancer
The trial will assess the efficacy, safety, and tolerability of daraxonrasib monotherapy in Asian patients with RAS-mutated advanced biliary tract cancer in second-line treatment.
- Trial name
- NCT07908550
- Testing
- Daraxonrasib
- Where
- Taiwan
- Volunteers
- 55 people
- Sponsor
- National Health Research Institutes, Taiwan
Biliary Tract Cancer, Disitamab Vedotin
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
This trial is a single-arm exploratory phase II clinical study initiated by the investigator. Subjects who met the research criteria were screened and enrolled to receive the treatment regimen of disitamab vedotin combined with…
- Conditions
- Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib, Immune Checkpoint Inhibitors
- Trial name
- NCT07159217
- Testing
- Disitamab Vedotin, Lenvatinib, Pembrolizumab
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking Union Medical College Hospital